Summary by Moomoo AI
CRISPR Therapeutics AG, a biotechnology company, has filed a Registration Statement on Form S-8 with the Securities and Exchange Commission on August 5, 2024. The filing is for the purpose of registering an additional 1,000,000 common shares at CHF 0.03 per share under the CRISPR Therapeutics AG 2018 Stock Option and Incentive Plan. This move is to facilitate the issuance of stock options and incentive plans to employees and directors. The registration statement incorporates by reference the contents of previous filings related to the 2018 Plan. The company, headquartered in Zug, Switzerland, with executive offices in South Boston, MA, is listed as a large accelerated filer. The filing includes various exhibits, such as the opinion of Swiss counsel regarding the validity of the common shares and the consent of Ernst & Young LLP as the independent registered public accounting firm.